Relative Drug Exposures Of Two Formulations of PF-02341066

NCT00939731 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer